UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (756) 756
science & technology (724) 724
life sciences & biomedicine (718) 718
female (577) 577
male (574) 574
hematology (563) 563
transplantation (498) 498
adult (473) 473
middle aged (447) 447
myeloablative agonists - administration & dosage (407) 407
immunology (345) 345
transplantation conditioning - methods (326) 326
myeloablative agonists - therapeutic use (310) 310
adolescent (294) 294
transplantation, homologous (286) 286
stem cells (279) 279
oncology (268) 268
hematopoietic stem cells (266) 266
aged (261) 261
hematopoietic stem cell transplantation (240) 240
biological and medical sciences (220) 220
medical sciences (217) 217
hematology, oncology and palliative medicine (213) 213
retrospective studies (206) 206
child (201) 201
treatment outcome (200) 200
vidarabine - analogs & derivatives (195) 195
transplantation conditioning (194) 194
myeloablative agonists - adverse effects (186) 186
busulfan - administration & dosage (172) 172
child, preschool (167) 167
disease-free survival (163) 163
survival analysis (148) 148
hematopoietic stem cell transplantation - methods (146) 146
graft vs host disease - prevention & control (144) 144
young adult (143) 143
melphalan - administration & dosage (137) 137
vidarabine - administration & dosage (134) 134
hematopoietic stem cell transplantation - adverse effects (128) 128
care and treatment (124) 124
health aspects (124) 124
biophysics (121) 121
transplantation, autologous (121) 121
infant (118) 118
analysis (113) 113
hematologic and hematopoietic diseases (113) 113
transplantation conditioning - adverse effects (113) 113
hematologic neoplasms - therapy (112) 112
follow-up studies (111) 111
busulfan (109) 109
risk factors (109) 109
bone marrow (107) 107
survival rate (106) 106
recurrence (104) 104
cyclophosphamide - administration & dosage (103) 103
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (102) 102
transfusions. complications. transfusion reactions. cell and gene therapy (102) 102
bone marrow, stem cells transplantation. graft versus host reaction (100) 100
graft vs host disease - mortality (100) 100
cancer (99) 99
dosage and administration (98) 98
stem cell transplantation (97) 97
mortality (95) 95
prospective studies (82) 82
research (81) 81
chemotherapy (80) 80
cyclophosphamide (77) 77
graft vs host disease - etiology (72) 72
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (71) 71
remission induction (71) 71
fludarabine (70) 70
immunosuppressive agents - therapeutic use (69) 69
melphalan (69) 69
combined modality therapy (67) 67
multiple myeloma - therapy (67) 67
pediatrics (67) 67
whole-body irradiation (66) 66
animals (65) 65
bone marrow transplantation (64) 64
busulfan - adverse effects (64) 64
prognosis (64) 64
antineoplastic combined chemotherapy protocols - therapeutic use (63) 63
hematologic neoplasms - mortality (63) 63
immunosuppressive agents - administration & dosage (63) 63
leukemia (63) 63
vidarabine - therapeutic use (63) 63
graft vs host disease - immunology (62) 62
multiple myeloma (62) 62
hematopoietic stem cell transplantation - mortality (60) 60
leukemia, myeloid, acute - therapy (60) 60
patient outcomes (60) 60
time factors (60) 60
busulfan - therapeutic use (58) 58
antineoplastic agents (57) 57
graft survival (57) 57
acute disease (56) 56
cyclophosphamide - therapeutic use (53) 53
melphalan - adverse effects (50) 50
busulfan - pharmacokinetics (49) 49
drug administration schedule (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (784) 784
French (3) 3
Russian (3) 3
Chinese (2) 2
German (2) 2
Danish (1) 1
Hungarian (1) 1
Japanese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of blood and marrow transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2017, Volume 66, Issue 11, pp. 1425 - 1436
Persistence | Immunology | Medicine & Public Health | Chimeric antigen receptor | Toxicity | Oncology | Cancer Research | T cells | CEA | Life Sciences & Biomedicine | Science & Technology | Cyclophosphamide - administration & dosage | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Carcinoembryonic Antigen - genetics | Drug Resistance, Neoplasm | Male | Interferon-gamma - metabolism | Myeloablative Agonists - agonists | Cyclophosphamide - adverse effects | T-Lymphocytes - transplantation | Carcinoembryonic Antigen - metabolism | Neoplasms - therapy | Neoplasms - genetics | T-Lymphocytes - metabolism | Adult | Female | Receptors, Antigen, T-Cell - immunology | Lung - metabolism | Interleukin-6 - metabolism | Anemia - etiology | Immunotherapy, Adoptive - adverse effects | Immunotherapy, Adoptive - methods | Abdominal Pain - etiology | GPI-Linked Proteins - immunology | Receptors, Antigen, T-Cell - metabolism | Carcinoembryonic Antigen - immunology | Vidarabine - adverse effects | Treatment Outcome | Vidarabine - analogs & derivatives | GPI-Linked Proteins - metabolism | Neoplasms - immunology | Interferon-gamma - immunology | Interleukin-6 - immunology | Vomiting - etiology | T-Lymphocytes - immunology | Aged | Receptors, Antigen, T-Cell - genetics | Vidarabine - administration & dosage | Cohort Studies | GPI-Linked Proteins - genetics | CEA (Oncology) | Cells | Cytokines | Control methods | Feasibility studies | Lymphocytes T | Malignancy | Epithelium | Patients | Interleukin 6 | Infusion | Carcinoembryonic antigen | Cyclophosphamide | Cell activation | Fludarabine | Interleukin 2 | Lungs | Lymphocytes | Production methods | γ-Interferon | Biocompatibility | Preconditioning | Index Medicus | Original
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4630 - 4634
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5530 - 5536
Journal Article
American journal of hematology, ISSN 0361-8609, 10/2018, Volume 93, Issue 10, pp. 1211 - 1219
Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Confidence Intervals | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Humans | Middle Aged | Drug Evaluation | Male | Living Donors | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Allografts | Bone Marrow Transplantation | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Proportional Hazards Models | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Thiotepa - adverse effects | Cyclophosphamide | Transplantation | Comparative analysis | Thiotepa | Stem cells | Fludarabine | Cord blood | Donors | Transplants & implants | Myeloid leukemia | Leukemia | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article
Journal Article